Articles
Mesoblast's new appointments "increase global visibility"
Mesoblast's (ASX:MSB) hiring of a former Novartis CFO so soon after former Roche executive William Burns joined its board may help the company pursue international partnership deals, Bell Potter said. [ + ]
GTG breast cancer test found to be cost-effective
Genetic Technologies (ASX:GTG) said economic modelling has shown the cost-effectiveness of using BREVAGen to help direct chemoprevention to women at elevated risk of breast cancer. [ + ]
Fibrotech completes phase Ia trial, moves to 1b
Fibrotech said a phase Ia trial has demonstrated the safety of antifibrotic candidate FT011 in healthy volunteers, and revealed the company has started dosing for a phase IIb study. [ + ]
China Summit paves the way for Australian companies
Recognising the leading role China will take globally in the future of life sciences, AusBiotech recently presented the second Australia China Life Science Summit in Sydney and now continues to pave the way for Australian companies interested in opportunities in and with China. [ + ]
Wireless monitoring systems for critical applications in life science facilities
Users need to be aware that not all monitoring systems are equal. Choosing the right system is paramount to product protection and adding value to your process. [ + ]
Biotron shares surge 123% on HIV/HCV trial data
Biotron (ASX:BIT) has announced promising additional early results from a trial of BIT225 in patients with both HIV and HCV. [ + ]
ESO telescope finds its MUSE
An innovative instrument called MUSE (Multi Unit Spectroscopic Explorer) has been successfully installed on the European Southern Observatory's (ESO) Very Large Telescope (VLT) at the Paranal Observatory in Chile. [ + ]
PolyNovo gets US tick for NovoPore dressing
Calzada's (ASX:CZD) PolyNovo subsidiary has won 510(k) approval in the US for TNP foam dressing NovoPore, which has become the first approved product based on its NovoSorb technology. [ + ]
Viralytics kicks off STORM cancer trial
Viralytics (ASX:VLA) has commenced a clinical trial involving delivering multiple intravenous doses of Cavatak to treat late-stage melanoma, prostate, lung and metastatic bladder cancers. [ + ]
In-transition Novogen names new directors
Novogen (ASX:NRT) has named two new directors, including the lead inventor of its new ATM cancer drug platform, and revealed it swung to a 1H14 loss. [ + ]
Mesoblast well funded for next 2-3 years
Bell Potter Securities has maintained its 'buy' rating for Mesoblast shares - with a slightly reduced price target - on the strength of the company's 1H14 results. [ + ]
Calzada appoints new director, posts 1H14 results
Calzada (ASX:CZD) has appointed David Williams as a non-executive director and revealed it improved its cash position during 1H14. [ + ]
Nanoparticles, peptides and paper to detect cancer
Engineers at Massachusetts Institute of Technology (MIT) have developed a cheap and simple diagnostic, much like a pregnancy test, which detects cancer in urine samples. [ + ]
No progress for Pharma Patents Review
No plan to release the Pharmaceutical Patents Review Report, says Minister for Industry, Ian Macfarlane. [ + ]
Ellex gets CE mark for laser eye treatment
Ellex Medical Lasers (ASX:ELX) has been granted approval to market 2RT - a laser therapy for chronic eye disease AMD - in the European Union. [ + ]
